Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resi… Read more
Arno Therapeutics (ARNI) - Net Assets
Latest net assets as of September 2016: $-5.71 Million USD
Based on the latest financial reports, Arno Therapeutics (ARNI) has net assets worth $-5.71 Million USD as of September 2016.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.36 Million) and total liabilities ($8.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.71 Million |
| % of Total Assets | -242.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Arno Therapeutics - Net Assets Trend (2012–2015)
This chart illustrates how Arno Therapeutics's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arno Therapeutics (2012–2015)
The table below shows the annual net assets of Arno Therapeutics from 2012 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $-8.62 Million | -391.40% |
| 2014-12-31 | $2.96 Million | +123.64% |
| 2013-12-31 | $-12.52 Million | -10.15% |
| 2012-12-31 | $-11.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arno Therapeutics's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4339417100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.47K | % |
| Other Components | $84.67 Million | % |
| Total Equity | $-8.62 Million | 100.00% |
Arno Therapeutics Competitors by Market Cap
The table below lists competitors of Arno Therapeutics ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RENALYTIX SP.ADS/2
F:2O9A
|
$1.50K |
|
Orchard Funding Group PLC
LSE:ORCH
|
$1.51K |
|
Nasdaq Global Travel and Leisur
STU:A4E1
|
$1.51K |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
$1.51K |
|
Spirits Time International Inc
PINK:SRSG
|
$1.50K |
|
Amper SA
MU:APR
|
$1.50K |
|
Mix1 Life Inc
PINK:MIXX
|
$1.50K |
|
ECOFIN US REN.IN. DL -01
F:9FV
|
$1.50K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arno Therapeutics's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from -588,891 to -8,624,094, a change of -8,035,203.
- Net loss of 11,507,963 reduced equity.
- Other factors increased equity by 3,472,760.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.51 Million | -133.44% |
| Other Changes | $3.47 Million | +40.27% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Arno Therapeutics's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Arno Therapeutics utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.16 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.37 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $7.83 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.65 Million |
Industry Comparison
This section compares Arno Therapeutics's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arno Therapeutics (ARNI) | $-5.71 Million | 0.00% | N/A | $1.50K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |